Symplicity Spyral Multi-electrode Renal Denervation Catheter (Image courtesy of Medtronic) The medtech giant isn’t giving up yet on renal denervation, if a new announcement is any indication. Chris Newmarker Medtronic is ...
Tags: Medtronic, Chris Newmarker, Medicine
ReCor Medical has announced major advances in its Paradise System for renal denervation (RDN), confirming its commitment to lead in the treatment of patients with resistant hypertension (HTN). The company announced that it has received ...
Tags: renal denervation system, health, HTN
Renal denervation as a high blood pressure treatment is looking less exciting by the day, with the latest bad news coming from Covidien. The Dublin, Ireland–based medical device giant said Tuesday that it will exit its OneShot renal ...
Posted in Cardiovascular by Chris Newmarker on January 15, 2014 Boston Scientific CEO Mike Mahoney remains optimistic about renal denervation and the company’s Vessix platform, even though Medtronic’s Symplicity system failed ...
Tags: Boston Scientific, Mike Mahoney, renal denervation, Vessix platform
Medtronic willfully infringed on an Edwards Lifesciences’ patent with its CoreValve transcatheter heart valve, and owes Edwards nearly $394 million in damages and patent royalties, a federal jury in Delaware found Wednesday. Edwards ...
Tags: Medtronic, CoreValve, transcatheter heart valve, Edwards
US-based medical technology company Medtronic has announced the randomization of the first patients in the SYMPLICITY HTN-4 clinical trial at Medical University of South Carolina, Piedmont Heart Institute and Duke University Medical Center. ...
Medtronic has unveiled new data from the Global SYMPLICITY Registry, a multi-centre, prospective, observational registry designed to collect comprehensive data evaluating procedural and long-term safety of the Symplicity renal denervation ...
Tags: Medtronic, Symplicity Registry
St. Jude Medical, a medical device firm, has announced that its EnligHTN Multi-Electrode Renal Denervation System offers a safe, rapid and sustained reduction in measurements of blood pressure after a year. The company presented the new ...
Tags: EnligHTN Renal, Blood Pressure
Medtronic has completed randomizing Symplicity HTN-3, a clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure that decreases the ...
Tags: Medtronic, Randomizing Symplicity
Medtronic has submitted its investigational device exemption (IDE) application to the FDA to initiate a study of its Symplicity renal denervation system for the treatment of uncontrolled hypertension in patients with systolic blood pressure ...
Early phase medical device company ROX Medical has completed enrolling first two Irish patients in a controlled, randomized study of its FLOW procedure for the treatment of resistant hypertension. The FLOW procedure is a minimally ...
Tags: ROX Medical, medical device, Medical
St Jude Medical is planning to begin EnligHTNment study, designed to evaluate whether patients with hypertension treated with its EnligHTN renal denervation system can provide additional benefits beyond a reduction in blood pressure. The ...
Tags: Medical, minimally invasive device, EnligHTN
St Jude Medical has enrolled the first patient in EnligHTN II trial of its multi-electrode renal denervation technology for treating patients with drug-resistant hypertension. The CE-marked EnligHTN renal denervation system, which ...
Tags: EnligHTN II trial, Medical, drug resistant hypertension
Covidien has introduced a new therapeutic device to treat patients with resistant hypertension. The CE-marked OneShot Renal Denervation system is an over the wire balloon-based irrigated catheter device which is implanted under the skin ...
Tags: Denervation System, Health, Medicine, resistant hypertension
St Jude Medical's multi-electrode renal denervation technology was proven to be safe and effective and showed sustained reduction in office and ambulatory blood pressure measurements, at six months post treatment in patients with ...